Over 68 weeks in the REDEFINE trials, cagrilintide 2.4 mg alone achieved approximately 10.8% body weight reduction
The confirmatory secondary endpoints included the change in the 6-min walking distance, a hierarchical composite of death and heart failure events
This confirms the well-documented role of cobalamin in lowering homocysteine levels in deficient or at-risk individuals
But how does it compare to more traditional strategies like glutamine, probiotics, or collagen

Potential Benefits Telomerase activation: induces expression of telomerase in human somatic cells, partially reversing telomere shortening associated with cellular aging and replicative senescence Melatonin regulation: restores age-related decline in pineal melatonin synthesis, supporting circadian rhythm normalization, sleep quality, and melatonin's anti-inflammatory and antioxidant functions Antioxidant enzyme support: modulates superoxide dismutase and catalase activity, reducing oxidative stress in aging tissues Circadian rhythm restoration: hypothalamic-pituitary axis modulation supporting normalization of daily hormonal cycles that deteriorate with age Investigated for all-cause mortality and cancer incidence reduction in elderly patients in multi-year human studies by the Khavinson research group Immune function support: melatonin-mediated immunomodulation and direct effects on lymphocyte activity investigated in aging populations Neuroprotection: antioxidant and anti-inflammatory effects in neural tissue relevant to cognitive aging Sleep quality improvement: melatonin restoration and circadian rhythm normalization produce clinically meaningful sleep improvements in patients with age-related sleep deterioration Gene expression modulation: Epitalon has been reported to normalize expression of genes associated with aging and cellular stress responses Oocyte quality: Epitalon has been investigated for reducing post-ovulatory aging-related damage in oocytes, relevant to reproductive aging research Speak with a physician Interested in Epitalon

Tirzepatide is an FDA-approved drug with completed Phase 3 obesity trials, while cagrilintide is investigational, with monotherapy data only through Phase 2 and its strongest results coming from the CagriSema combination